Sheba Medical Center and Swiss-based CDMO Lonza Pharma recently announced a new collaborative venture to use the cutting-edge CocoonTM manufacturing platform to develop point-of-care CAR T-cell therapy. This joint project aims to streamline the in-house cell manufacturing process, thereby enabling a greater amount of critically ill oncology patients to access genetically engineered human CAR T-cells more efficiently.

In February 2012, a family from Chelyabinsk, Russia faced a critical situation. Their 11-month old son, Dima, was seriously ill. Read about his touching recovery story and battle against leukemia.